This podcast brings you exclusive updates on multiple myeloma from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held in San Diego, CA. In this episode, experts Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA, Alexander Lesokhin, MD, Memorial Sloan Kettering Cancer Center, New York, NY, Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, Mansi Shah, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center & University of Miami, Miami, FL, and Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, share key insights from the meeting.
The discussion covers updates on smoldering myeloma, including the practice-changing results of the AQUILA (NCT03301220) study, as well as the latest advances in bispecific antibodies for relapsed/refractory multiple myeloma. The experts also highlight exciting research to watch for in 2025. Finally, they provide guidance on the use of measurable residual disease (MRD) and address the ongoing challenge of treating high-risk multiple myeloma.
The post Post-ASH myeloma highlights: key takeaways for community physicians & trials to look out for in 2025 appeared first on VJHemOnc.
